AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer | Zendy

Emmanuel S. Antonarakis | Zendy; Changxue Lu | Zendy; Hao Wang | Zendy; Brandon Luber | Zendy; Mari Nakazawa | Zendy; Jeffrey C. Roeser | Zendy; Yan Chen | Zendy; Tabrez A. Mohammad | Zendy; Yidong Chen | Zendy; Helen Fedor | Zendy; Tamara L. Lotan | Zendy; Qizhi Zheng | Zendy; Angelo M. De Marzo | Zendy; John T. Isaacs | Zendy; William B. Isaacs | Zendy; Rosa Nadal | Zendy; Channing J. Paller | Zendy; Samuel R. Denmeade | Zendy; Michael A. Carducci | Zendy; Mario A. Eisenberger | Zendy; Jun Luo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

Author(s) -

Emmanuel S. Antonarakis,

Changxue Lu,

Hao Wang,

Brandon Luber,

Mari Nakazawa,

Jeffrey C. Roeser,

Yan Chen,

Tabrez A. Mohammad,

Yidong Chen,

Helen Fedor,

Tamara L. Lotan,

Qizhi Zheng,

Angelo M. De Marzo,

John T. Isaacs,

William B. Isaacs,

Rosa Nadal,

Channing J. Paller,

Samuel R. Denmeade,

Michael A. Carducci,

Mario A. Eisenberger,

Jun Luo

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1315815

Subject(s) - enzalutamide , medicine , prostate cancer , androgen receptor , oncology , progression free survival , urology , cancer , chemotherapy

The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding domain, which is the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. We hypothesized that detection of androgen-receptor splice variant 7 messenger RNA (AR-V7) in circulating tumor cells from men with advanced prostate cancer would be associated with resistance to enzalutamide and abiraterone.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research